SCHEMBL3985464

SCHEMBL3985464

Cc1nn(Cc2ccccc2F)c(=O)c2c(O)c3n(c12)CCN(C)C3=O

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PKM P14618 5/20 0.46
PKLR P30613 5/20 0.46
KCNH2 Q12809 1/20 0.39
GRM2 Q14416 1/20 0.39
KMT2A Q03164 3/20 0.37
MEN1 O00255 1/20 0.37
MAOB P27338 1/20 0.36
ADORA2A P29274 1/20 0.36
ALDH1A1 P00352 3/20 0.36
TSHR P16473 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CYP1A2 P05177 2/20 0.35
CYP2C19 P33261 2/20 0.35
MAPT P10636 2/20 0.35
LMNA P02545 1/20 0.35
P2RX7 Q99572 1/20 0.35
CASR P41180 1/20 0.35
HPGD P15428 1/20 0.35
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3991515 0.92 PKM (0.38) PKMPKLRKCNH2GRM2KMT2A
SCHEMBL3986669 0.90 TSHR (0.38) PKMPKLRKMT2AMEN1ADORA2A
SCHEMBL3985526 0.89 PKM (0.38) PKMPKLRALDH1A1CYP1A2CYP2C19
SCHEMBL3985480 0.87 PKM (0.36) PKMPKLRP2RX7
SCHEMBL1386722 0.87 MEN1 (0.44) PKMKMT2AMEN1MAOBADORA2A
SCHEMBL3985461 0.86 PDE5A (0.39) KMT2AMEN1MAPTHPGD
SCHEMBL3986391 0.86 NPBWR1 (0.37) KMT2A
SCHEMBL3988165 0.85 SLC22A12 (0.41) KMT2AMEN1ALDH1A1P2RX7
SCHEMBL3983532 0.84 PKM (0.44) PKMPKLRKCNH2GRM2KMT2A
SCHEMBL3985346 0.83 PKM (0.36) PKMPKLRKCNH2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US claimed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US claimed
EP-1756114-B1 HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME (US) 2014-11-19 EP disclosed
EP-1756114-B1 HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME (US) 2014-11-19 EP disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287394-A1 Hiv Integrase Inhibitors DHPS, DPYD, TYMP PKM 1268/4885PKLR 519/4885KCNH2 1197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.